Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apararenone in NASH
NCT02923154Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing MT-3995 with Placebo (2 arms). Primary endpoint: Percent change from baseline in Alanine Aminotransferase at 24 weeks. Started Sep 2016; status: completed.
02
Drugs
apararenone
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02923154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923154.